PT -期刊文章盟Yeong Jeong AU - Chong Hyun Suh AU - Woo Hyun垫片盟Jae-Sung Lim AU - Jae-Hong李盟金唱俊TI - Amyloid-Related成像异常患者中发病率阿尔茨海默病治疗- 10.1212 / WNL Anti-β-Amyloid免疫治疗援助。0000000000201019 DP - 2022年11月08年TA -神经首页病学PG - e2092 e2101 VI - 99 IP - 19 4099 - //www.ez-admanager.com/content/99/19/e2092.short 4100 - //www.ez-admanager.com/content/99/19/e2092.full所以Neurology2022 11月08年;99 AB -背景和目标来评估amyloid-related成像异常的发生率(咏叹调)在临床试验中anti-β-amyloid (Aβ)免疫疗法和比较不同代理商之间的发生率和临床特征来识别可能的咏叹调的诱发因素。方法PubMed和Embase数据库寻找anti-Aβ免疫疗法的临床试验发表在1月12日或之前2022年。阶段2或3随机对照试验报告详细的数据足以评估选择咏叹调的发病率。咏叹调的总发生率和子群分析根据代理和ApoE-4载体状态用的DerSimonian-Liard随机影响模型计算。ARIA病例症状的比例也计算。结果总共19个符合条件的研究,包括24个军团,被识别和9429名患者进行了分析。整个池ARIA-effusion发病率(E)和ARIA-hemorrhage (H)是6.5%和7.8%,分别。亚组分析,根据anti-Aβ咏叹调的发病率不同免疫疗法的代理。治疗组与aducanumab发生率明显高于ARIA-E和ARIA-H(分别为30.7%和30.0%;p & lt; 0.001) compared with cohorts from other drugs. In subgroup analysis according to ApoE-4 carrier status, the incidences of ARIA-E and ARIA-H were higher in the ApoE-4 carrier group than those in the ApoE-4 noncarrier group, but there was no statistical significance (ApoE-4 carrier vs noncarrier, ARIA-E: 8.6% vs 6.9%, p = 0.663, and ARIA-H: 10.5% vs 6.6%, p = 0.398). The pooled proportion of asymptomatic ARIA, detected by routine scheduled MRI surveillances, was 80.4%.Discussion The overall incidences of ARIA-E and ARIA-H were 6.5% and 7.8%, respectively, and the pooled proportion of asymptomatic ARIA was 80.4%. The cohorts treated with aducanumab showed a significantly higher incidence of ARIA-E and ARIA-H (30.7% and 30.0%) compared with other drugs.Aβ=β-amyloid; AD=Alzheimer disease; ARIA=amyloid-related imaging abnormalities; ARIA-E=ARIA-effusion; ARIA-H=ARIA-hemorrhage; FDA=Food and Drug Administration